THE ROLE OF STUDYING PATHOGENIC STRAINS OF H. PYLORI AND MORPHOLOGICAL STUDIES IN THE EARLY DIAGNOSIS OF GASTRIC CANCER
Keywords:
H. рylori-associated diseases of the stomach, molecular genetic research, targeted biopsy,morphological studies, pathogenic strains H. pylori bacterium, OLGA system and the CagA gene.Abstract
The authors studied morphological changes in the gastric mucosa and the identification of pathogenic strains in 232 patients. The results of the study showed that the intensity of morphological changes in the stomach depends on the nosological forms of H. pylori-associated stomach diseases. All patients underwent gastroscopy with a five-core biopsy of the stomach. Based on the studied material, a morphological study of biopsy specimens was carried out to identify pretumor changes (fibrosis, atrophy, intestinal metaplasia, dysplasia) in patients with pylori-associated gastric diseases. The general interpretation of the results showed the expediency of using the OLGA system, since it is morphological analysis from the point of view of detecting atrophy and intestinal metaplasia that can be the most basic for the formation of the next strategy of therapeutic measures. It is clearly seen that the CagA gene is a risk factor for the development of severe forms of gastrointestinal diseases. From the point of view of diagnostic effectiveness, the CagA gene has been studied as an average indicator for all diseases, which means that this gene can be used as a marker gene in the diagnosis of pathogenic or non-pathogenic H.pylori strain.
References
Abdurakhimov A.A. Gastritis associated with Helicobacter pylori: abstract. diss.. – T., 2014. - 24 p. (in Uzb).
Bordin D.S., Livzan M. //Consensus Maastricht VI published: what’s new? Effective pharmacotherapy. 2022; 18 (22): 72–84. (in Russ).
Ismailova Zh.A., Yusupbekov A.A. // Morphological changes in the mucous membrane in Helicobacter pylori-associated gastric diseases. Therapeutic Bulletin of Uzbekistan, No. 4. - 2022 pp. 127-132. (in Uzb).
Tsukanov V.V., Tretyakova O.V., Amelchugova O.S. and others. Prevalence of atrophic gastritis of the body of the stomach in the population of Krasnoyarsk over 45 years old // Russian Journal of Gastroenterology, Hepatology, Coloproctology. - 2012. - T. 22. - No. 4. - P. 27-31. (in Russ).
Suzuki M., Mimuro H., Suzuki T., Park M., Yamamoto T., Sasakawa C. Interaction of CagA with Crk plays an important role in Helicobacter pylori–induced loss of gastric epithelial cell adhesion //Journal of Experimental Medicine. – 2005. – V.202. – №. 9. – P. 1235–1247.
Graham D.Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits //Gastroenterology. – 2015. – V.148. – №. 4. – P. 719–731.
Ismailova J.A., Yusupbekov А.А. CagA gene study - a new therapeutic way for eradication in patients with Нelicobacter pylori associated gastric diseases// Latin American Journal of Pharmacy (formerly Acta Farmacéutica Bonaerense) Lat. Am. J. Pharm. 42 (3): (2023). ISSN 0326-2383. Р.43-8
Wald N. J. The treatment of Helicobacter pylori infection of the stomach in relation to the possible prevention of gastric cancer. In: IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, № 8); 2014, p. 174–180.
Roberts, S. E., Morrison-Rees, S., Samuel, D. G., Thorne, K., Akbari, A., and Williams, J. G. (2016). Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment. Pharmacol. Ther. 43, 334–345. doi: 10.1111/apt.13474.
Статья поступила в редакцию 09.01.2024; одобрена после рецензирования 17.02.2024; принята к публикации 20.02.2024.
The article was submitted 09.01.2024; approved after reviewing 17.02.2024; accepted for publication 20.02.2024.
Информация об авторах:
Исмаилова Жадида Ахмеджановна- д.м.н., старший научный сотрудник, заместитель директора по научной работе. Республиканский специализированный научно-практический медицинский центр терапии и медицинской реабилитации, Ташкент, Узбекистан. Е-mail: jadida@list.ru https://orcid.org/0000-0001-7791-4714
Юсупбеков Аброржон Ахмеджанович - д.м.н., профессор, заместитель директора по научной работе. Республиканский специализированный научно-практический медицинский центр онкологии и радиологии, Ташкент, Узбекистан. Е-mail: dr.abr_info@mail.ru, https://orcid.org/0000-0002-7747-0989
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Исмаилова Ж.А. — идеологическая концепция работы, написание текста; редактирование статьи;
Юсупбеков А.А. — сбор и анализ источников литературы, написание текста.
Information about the authors:
Jadida A. Ismailova — DSc, associate professor, deputy director, Republican Specialized Scientific and Practical Center for Therapy and Medical Rehabilitation, Uzbekistan. Е-mail: jadida@list.ru https://orcid.org/0000-0001-7791-4714
Abrorjon A. Yusupbekov — DSc, professor, deputy director, Republican Specialized Scientific and Practical Center Oncology and Radiology, Uzbekistan; E-mail: dr.abr_info@mail.ru, https://orcid.org/0000-0002-7747-0989
Sources of funding: The work did not receive any specific funding.
Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.
Contribution of the authors:
Ismailova JA — ideological concept of the work, writing the text; editing the article;
Yusupbekov AA — collection and analysis of literature sources, writing the text.
